Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Schering
INDICATIONS [/za_1035.html#1] [/za_1035.html#1] [/za_1035.html#1] CONTRA-INDICATIONS [/za_1035.html#1] [/za_1035.html#1] DOSAGE [/za_1035.html#1] [/za_1035.html#1] SIDE-EFFECTS [/za_1035.html#1] [/za_1035.html#1] [/za_1035.html#6] PREGNANCY [/za_1035.html#6] [/za_1035.html#1] OVERDOSE [/za_1035.html#1] IDENTIFICATION [/za_1035.html#1] [/za_1035.html#1] PATIENT INFORMATION FEMODENE ED SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): FEMODENE ED TABLETS COMPOSITION The 28-day pack (Every-Day pack) contains 21 hormonal tablets each with GESTODENE (17alpha-ethinyl-13-ethyl- 17beta-hydroxy-4,15-gonadiene-3-one) 0,075 mg and ETHINYLESTRADIOL (17alpha-ethinyl-estra-1,3,5(10)-triene- 3,17beta-diol) 0,03 mg, plus 7 inactive tablets. PHARMACOLOGICAL CLASSIFICATION A. 21.8.2 Progesterones with estrogens. PHARMACOLOGICAL ACTION PHARMACODYNAMICS Femodene ED is a low-dose monophasic oral contraceptive with estrogenic and progestogenic peripheral effects. The contraceptive effect of Femodene ED is based on the interaction of various factors, the most important of which are seen as the inhibition of ovulation and the changes in the cervical secretion. PHARMACOKINETICS • Gestodene Absorption Orally administered gestodene is rapidly and completely absorbed. Peak serum concentrations of 4 ng/mL are reached at about 1 hour after single ingestion. Bioavailability is about 99%. Distribution Gestodene is bound to serum albumin and to sex hormone binding globulin (SHBG). Only 1 to 2% of the total serum drug concentration is present as free steroid, 50 to 70% is specifically bound to SHBG. The ethinylestradiol-induced increase in SHBG influences the distribution over the serum proteins, causing an increase of the SHBG-bound fraction and a decrease of the albumin-bound fractio Read the complete document